Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Diabetes Therapy Springer Nature Link Amylin Injectable Cagrilintide Demonstrates Weight Loss of 11.8% in Late Stage Trial: Novo Nordisk Update Patient Care Online Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as Cagrilintide and the Future of Obesity Therapeutics: Assessing Novo Nordisk's Next Generation Amylin Monotherapy as a Strategic Play in a $100B+ Market Cagrilintide Weight Loss Appetite Control and Fat Burning Support